What is Ultromics?
Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately using nothing more than a standard ultrasound scan. The company's innovative approach leverages advanced artificial intelligence to interpret echocardiograms, providing clinicians with faster and more precise diagnostic insights. This technology is crucial in addressing the growing global burden of cardiovascular disease, enabling earlier intervention and improved patient outcomes.
How much funding has Ultromics raised?
Ultromics has raised a total of $100.8M across 4 funding rounds:
Angel/Seed
$2.8M
Series A
$10M
Series B
$33M
Series C
$55M
Angel/Seed (2017): $2.8M with participation from Oxford Sciences Enterprises
Series A (2018): $10M, investors not publicly disclosed
Series B (2021): $33M supported by The Blue Venture Fund, GV, and Optum Ventures
Series C (2025): $55M featuring Oxford University, Allegis Capital, Blue Ventures, Lightrock, Oxford Sciences Enterprises, The University of Chicago, and Google
Key Investors in Ultromics
Oxford University
The University of Oxford, a prestigious British research institution, is a foundational backer of Ultromics, contributing to its academic origins and technological development.
Allegis Capital
Allegis Capital is a venture capital firm dedicated to supporting visionary founders from inception through IPO, providing essential resources and strategic guidance for scaling innovative companies.
Lightrock
Lightrock is a global sustainable investment platform focused on backing purpose-driven businesses that address significant global challenges, aiming for both impact and financial returns.
What's next for Ultromics?
With a substantial total funding of $100.8M, Ultromics is well-positioned for significant growth and market expansion. The recent capital injection, though undisclosed, signals strong investor confidence in the company's technology and its potential to disrupt the cardiovascular diagnostics market. This strategic financing will likely fuel further research and development, enhance the capabilities of the EchoGo® platform, and support broader commercialization efforts. Ultromics is poised to solidify its leadership in AI-driven healthcare solutions, aiming to transform how heart disease is diagnosed and treated on a global scale.
See full Ultromics company page
